{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:00:45Z","timestamp":1760058045999,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Faculty of medicine, Thammasat University","award":["1-07\/2565"],"award-info":[{"award-number":["1-07\/2565"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Few reports exist regarding the incidence and factors associated with allergic reactions to COVID-19 vaccines during post-marketing surveillance, especially for inactivated whole virus or viral vector vaccines. We aimed to determine the incidence and factors associated with self-reported allergic reactions to COVID-19 vaccines in the Thai population. Methods: A cross-sectional case-control study was conducted via telephone-based interviews. Cases were defined as physician-confirmed, self-reported vaccine recipients diagnosed with non-severe immediate allergic reactions, anaphylaxis, or delayed allergic reactions. Controls were randomly sampled from vaccinated individuals who reported no adverse events and were matched by the type of vaccine (1 case:2 controls). Demographic information and the history of atopic diseases were collected in both groups. Conditional logistic regression analysis was used to explore associated factors. Results: Among 215,079 vaccine doses administered, the incidence of self-reported skin symptoms of allergic reactions was 1821 events (0.85%). The risk factors for allergic reactions included age &lt; 60 years (aOR 3.53; 95% CI:1.43\u20138.70; p = 0.006), female sex (aOR 8.33; 95% CI: 4.35\u201315.94; p &lt; 0.001), a personal history of allergic rhinitis (aOR 4.32; 95% CI: 2.43\u20137.69; p &lt; 0.001), atopic dermatitis (aOR 4.27; 95% CI: 1.74\u201310.47; p = 0.002), food allergies (aOR 6.53; 95% CI: 2.42\u201317.61; p &lt; 0.001), and a family history of allergic disease (aOR 2.14; 95% CI: 1.12\u20134.08; p = 0.021). Conclusions: COVID-19 vaccines showed a low incidence of self-reported allergic reactions, which were more likely to occur in younger individuals, females, and those with a history of atopic diseases.<\/jats:p>","DOI":"10.3390\/vaccines13030289","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T06:59:59Z","timestamp":1741589999000},"page":"289","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Incidence and Factors Associated with Self-Reported Skin Symptoms of Allergic Reactions to COVID-19 Vaccines"],"prefix":"10.3390","volume":"13","author":[{"given":"Karnsinee","family":"Thanborisutkul","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand"},{"name":"Center of Excellence for Allergy, Asthma and Pulmonary Disease, Thammasat University Hospital, Thammasat University, Pathum Thani 12120, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prapasri","family":"Kulalert","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand"},{"name":"Center of Excellence for Allergy, Asthma and Pulmonary Disease, Thammasat University Hospital, Thammasat University, Pathum Thani 12120, Thailand"},{"name":"Department of Clinical Epidemiology, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanthida","family":"Methaset","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Thammasat University Hospital, Thammasat University, Pathum Thani 12120, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3196-4657","authenticated-orcid":false,"given":"Sira","family":"Nanthapisal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand"},{"name":"Center of Excellence for Allergy, Asthma and Pulmonary Disease, Thammasat University Hospital, Thammasat University, Pathum Thani 12120, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibet","family":"Chunthatikul","sequence":"additional","affiliation":[{"name":"Doctor of Medicine Program, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathamon","family":"Phangpanya","sequence":"additional","affiliation":[{"name":"Doctor of Medicine Program, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phenpraphatson","family":"Charoenying","sequence":"additional","affiliation":[{"name":"Doctor of Medicine Program, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Worakamon","family":"Atsawutmangkru","sequence":"additional","affiliation":[{"name":"Doctor of Medicine Program, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suphatsara","family":"Srijaroen","sequence":"additional","affiliation":[{"name":"Doctor of Medicine Program, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6799-3954","authenticated-orcid":false,"given":"Patcharaporn","family":"Punyashthira","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand"},{"name":"Center of Excellence for Allergy, Asthma and Pulmonary Disease, Thammasat University Hospital, Thammasat University, Pathum Thani 12120, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orapan","family":"Poachanukoon","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand"},{"name":"Center of Excellence for Allergy, Asthma and Pulmonary Disease, Thammasat University Hospital, Thammasat University, Pathum Thani 12120, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/JCMA.0000000000000270","article-title":"The outbreak of COVID-19: An overview","volume":"83","author":"Wu","year":"2020","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/thoraxjnl-2020-215518","article-title":"Managing intensive care admissions when there are not enough beds during the COVID-19 pandemic: A systematic review","volume":"76","author":"Tyrrell","year":"2021","journal-title":"Thorax"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41591-020-1112-0","article-title":"Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries","volume":"26","author":"Kontis","year":"2020","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-022-00996-y","article-title":"COVID-19 vaccine development: Milestones, lessons and prospects","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/jama.2021.1967","article-title":"Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US\u2014December 14, 2020\u2013January 18, 2021","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s40264-021-01104-9","article-title":"Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report","volume":"44","author":"Iguchi","year":"2021","journal-title":"Drug Saf."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bian, S., Li, L., Wang, Z., Cui, L., Xu, Y., Guan, K., and Zhao, B. (2022). Allergic Reactions After the Administration of COVID-19 Vaccines. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.878081"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1016\/j.jaip.2022.07.027","article-title":"Incidence and Risk Factors of Immediate Hypersensitivity Reactions and Immunization Stress-Related Responses with COVID-19 mRNA Vaccine","volume":"10","author":"Imai","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e2122255","DOI":"10.1001\/jamanetworkopen.2021.22255","article-title":"Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults with High Allergy Risk","volume":"4","author":"Shavit","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1016\/j.vaccine.2021.06.058","article-title":"Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration","volume":"39","author":"Desai","year":"2021","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jaip.2020.12.047","article-title":"mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach","volume":"9","author":"Banerji","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.13562","article-title":"EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity","volume":"74","author":"Brockow","year":"2019","journal-title":"Allergy"},{"key":"ref_18","unstructured":"US Food and Drug Administration (2021, December 22). Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/development-and-licensure-vaccines-prevent-covid-19."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/j.vaccine.2022.11.027","article-title":"Anaphylaxis: Revision of the Brighton collaboration case definition","volume":"41","author":"Gold","year":"2023","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101595","DOI":"10.1016\/j.pmedr.2021.101595","article-title":"Early solicited adverse events following the BNT162b2 mRNA vaccination, a population survey from Saudi Arabia","volume":"24","author":"Almohaya","year":"2021","journal-title":"Prev. Med. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e2131034","DOI":"10.1001\/jamanetworkopen.2021.31034","article-title":"Association of Self-reported High-Risk Allergy History with Allergy Symptoms After COVID-19 Vaccination","volume":"4","author":"Li","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5415\/apallergy.2017.7.3.156","article-title":"Self-report prevalence and associated factors to drug hypersensitivity in Mexican young adults","volume":"7","year":"2017","journal-title":"Asia Pac. Allergy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaip.2021.12.021","article-title":"Population-Based Incidence, Severity, and Risk Factors Associated with Treated Acute-Onset COVID-19 mRNA Vaccination-Associated Hypersensitivity Reactions","volume":"10","author":"Macy","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1001\/jama.2021.3976","article-title":"Acute Allergic Reactions to mRNA COVID-19 Vaccines","volume":"325","author":"Blumenthal","year":"2021","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Paoletti, G., Pepys, J., Bragato, M.C., Paoletti, S., Piona, A., Messina, M.R., Racca, F., Ferri, S., Nappi, E., and Costanzo, G. (2023). The Prevalence of Immediate Hypersensitivity Reactions to the BNT162b2 mRNA Vaccine against SARS-CoV-2: Data from the Vaccination Campaign in a Large Academic Hospital. Vaccines, 11.","DOI":"10.3390\/vaccines11050903"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/3\/289\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:49:50Z","timestamp":1760028590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/3\/289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["vaccines13030289"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13030289","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2025,3,10]]}}}